In a crossover RCT of 17 healthy men, duodenal infusion of recombinant RORDEP1 (a gut-bacteria peptide) after a liquid meal versus placebo was well tolerated and caused an early rise in GLP-1, insulin and C-peptide and falls in GIP and glucose.
RCTn = 17
Gæde et al. A randomised clinical trial testing the safety of and metabolic responses to short-term duodenal infusion of recombinant RORDEP1 in healthy men